Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14712598.2021.1965985 http://scihub22266oqcxt.onion/10.1080/14712598.2021.1965985 34357839!ä!34357839 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Biol+Ther 2021 ; 21 (11): 1535-1537 Nephropedia Template TP {{tp|p=34357839|t=2021. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents |pdf=|usr=}}{{34357839}} gab.com Text Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents JO: Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=34357839 #FOAvip Introduction: There is very limited kn3e safety of COVID-19 vaccines in patients with psoriasis who are being treated with biological agents. We present our experience in 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL agents who were vaccinated against SARS-CoV-2.Areas covered: None of the 369 patients referred to any serious adverse event related to vaccination against COVID-19, while about one-third reported mild adverse events similar to those seen in the general population that were resolved within 48 hours. No patient discontinued biological therapy to receive a COVID-19 vaccine.Expert opinion: Our observations provide evidence that COVID-19 vaccines can be considered safe in patients with moderate-to-severe psoriasis who are receiving anti-IL therapy. Twit Text FOAVip Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents ????Expert Opin Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=34357839 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34357839 #FOAvip English Wikipedia <ref>{{Cite pmid|34357839}}</ref> Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents #MMPMID34357839 Talamonti M; Galluzzo M Expert Opin Biol Ther 2021[Nov]; 21 (11): 1535-1537 PMID34357839show ga Introduction: There is very limited kn3e safety of COVID-19 vaccines in patients with psoriasis who are being treated with biological agents. We present our experience in 369 patients with moderate-to-severe psoriasis undergoing therapy with anti-IL agents who were vaccinated against SARS-CoV-2.Areas covered: None of the 369 patients referred to any serious adverse event related to vaccination against COVID-19, while about one-third reported mild adverse events similar to those seen in the general population that were resolved within 48 hours. No patient discontinued biological therapy to receive a COVID-19 vaccine.Expert opinion: Our observations provide evidence that COVID-19 vaccines can be considered safe in patients with moderate-to-severe psoriasis who are receiving anti-IL therapy. |*COVID-19[MESH] |*Psoriasis/drug therapy[MESH] |Biological Factors[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH]Safety of COVID-19 vaccines in patients with psoriasis undergoing ther(epmc).pdf DeepDyve Pubget Overpricing